| 1.07 0.08 (8.08%) | 06-26 14:24 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.36 |
1-year : | 1.5 |
| Resists | First : | 1.16 |
Second : | 1.28 |
| Pivot price | 1.09 |
|||
| Supports | First : | 0.96 | Second : | 0.8 |
| MAs | MA(5) : | 1.01 |
MA(20) : | 1.1 |
| MA(100) : | 1.04  |
MA(250) : | 1.51 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 8.1 |
D(3) : | 10.1 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 3.68 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GDTC ] has closed above bottom band by 20.0%. Bollinger Bands are 16.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.04 - 1.05 | 1.05 - 1.05 |
| Low: | 0.98 - 0.98 | 0.98 - 0.99 |
| Close: | 0.98 - 0.99 | 0.99 - 1 |
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Fri, 26 Jun 2026
CytoMed Therapeutics Limited Actuals & Estimates (NASDAQ:GDTC) - TradingView
Tue, 23 Jun 2026
Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com - Investing.com Nigeria
Tue, 23 Jun 2026
CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D - Stock Titan
Mon, 22 Jun 2026
CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Thu, 18 Jun 2026
CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mon, 15 Jun 2026
CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 67.8 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 68 (K) |
| Shares Short P.Month | 68 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | 0 % |
| Operating Margin | -535.3 % |
| Return on Assets (ttm) | -29.4 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 46.9 % |
| Gross Profit (p.s.) | 0.06 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -3.85 |
| PEG Ratio | 0 |
| Price to Book value | 2.32 |
| Price to Sales | 13.74 |
| Price to Cash Flow | -3.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|